Learning disabilities

Alzheimer's Drug Discovery Foundation (ADDF) Investment Boosts Search for Digital Biomarkers for Early Alzheimer's

Retrieved on: 
Monday, July 26, 2021
Branches of biology, Biology, Psychiatry, Psychiatric diagnosis, Cognitive disorders, Learning disabilities, Dementia, Aging-associated diseases, Alzheimer's disease, Alzheimer's Drug Discovery Foundation, Biomarker, Ronald Lauder

The Diagnostics Accelerator provides funding to fast-track the development of affordable and accessible diagnostic tools and biomarkers for Alzheimer's disease and related dementias.

Key Points: 
  • The Diagnostics Accelerator provides funding to fast-track the development of affordable and accessible diagnostic tools and biomarkers for Alzheimer's disease and related dementias.
  • Recent research shows that Alzheimer'salso causes subtle early changes in aspects of behaviour such as sleep, speech, interactions, and movement.
  • While undetectable to the human eye, these changes can now be picked up by commercially available digital technologies.
  • Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer's disease.

Improving Air Quality Reduces Dementia Risk, Multiple Studies Suggest

Retrieved on: 
Monday, July 26, 2021
Psychiatry, Psychiatric diagnosis, Cognitive disorders, Learning disabilities, Branches of biology, Aging-associated diseases, Abnormal psychology, Pollution, Dementia, Air pollution

While research has linked air quality and cognition previously, these new data at AAIC 2021 explore how air pollutants might impact dementia and what reducing them might mean for long-term brain health.

Key Points: 
  • While research has linked air quality and cognition previously, these new data at AAIC 2021 explore how air pollutants might impact dementia and what reducing them might mean for long-term brain health.
  • "But what's exciting is we're now seeing data showing that improving air quality may actually reduce the risk of dementia.
  • Air Quality Improvement May Slow Cognitive Decline and Reduce Dementia Risk in Older U.S. Women
    Although studies have found that improved air quality is associated with better respiratory health and longer life expectancy, it's unknown if improved air quality can also improve brain health.
  • Association of air quality reduction with incident dementia: effects of natural course and hypothetical air pollutant interventions using g-computation.

Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimer’s Disease with Vascular Pathology at the Alzheimer’s Association International Conference 2021 (AAIC)

Retrieved on: 
Thursday, July 22, 2021
Psychiatry, Branches of biology, Psychiatric diagnosis, Health sciences, Cognitive disorders, Learning disabilities, Aging-associated diseases, Dementia, Alzheimer's disease, Clinical trial

This pioneering work provides insights into the relationships between electrophysiological measures and cognitive performance in patients with Alzheimers disease and other dementias.

Key Points: 
  • This pioneering work provides insights into the relationships between electrophysiological measures and cognitive performance in patients with Alzheimers disease and other dementias.
  • Cyclerion identified changes in electrophysiological measures in the recent Phase 1 Translational Pharmacology study and will be evaluating electrophysiological and cognitive endpoints in the Phase 2a study in participants with Alzheimers disease with vascular pathology.
  • Title: Clinical trial design for a Phase 2a study evaluating the safety, tolerability, pharmacokinetics, and CNS activity of CY6463 in participants with Alzheimers disease with vascular pathology
    The poster presentation will be available beginning at 8 a.m. MT / 10 a.m.
  • The poster will also be available on the News & Events page of the Cyclerion website https://ir.cyclerion.com/news-events/event-calendar .

The Virginian Senior Living Community Launches Obie For Seniors Interactive Gaming System

Retrieved on: 
Wednesday, July 21, 2021
Psychiatry, Branches of biology, Cognitive disorders, Learning disabilities, Psychiatric diagnosis, Neuroscience, Dementia, Alzheimer's disease

Obie for Seniors is an award-winning interactive gaming system that projects onto any surface - tabletops, floors, and walls - encouraging active play through touching, moving, and hand-eye coordination skills.

Key Points: 
  • Obie for Seniors is an award-winning interactive gaming system that projects onto any surface - tabletops, floors, and walls - encouraging active play through touching, moving, and hand-eye coordination skills.
  • The system is among the newest "Nana" Technology being adopted for use in the United States for individuals with Alzheimer's and related dementia.
  • Based in Israel, EyeClick is a world leader in interactive technology for 15+ years and the creator of Obie for Seniors.
  • Obie helps to enhance the conditions of senior housing facilities, hospitals, and clinics with tailored interactive games that provide residents with engagement, fun, and encourages increased mobility and cognitive skills.

Eisai to Present Latest Data on Pipeline Assets in The Area of Alzheimer's Disease and Dementia at AAIC 2021

Retrieved on: 
Wednesday, July 21, 2021
Life sciences, Psychiatry, Branches of biology, Cognitive disorders, Learning disabilities, Psychiatric diagnosis, Biogen, Spinal muscular atrophy, Eisai, Dementia, Alzheimer's disease
Key Points: 
  • A poster presentation will also be given on the results of an in vivo study of E2511, Eisai's in-house discovered and developed investigational novel oral synapse regenerant.
  • Additionally, Eisai and Biogen Inc. (Nasdaq: BIIB) will hold a virtual symposium, "Defining the next-generation clinical care pathway for Alzheimer's disease: biological, technological, and healthcare perspectives," focusing on the AD treatment landscape.
  • Eisai serves as the lead in the co-development of lecanemab, an anti-Aβ protofibril antibody, which is being jointly developed by Eisai and Biogen.
  • Eisai aims to realize the prevention and cure of dementia through a multi-dimensional and holistic approach with a foundation of over 35 years of experience of drug discovery activities in the area of AD and dementia.

Regencell Bioscience Holdings Limited Announces Closing of Initial Public Offering

Retrieved on: 
Tuesday, July 20, 2021
Mental health, Health, Genetics, Other Science, Science, Pharmaceutical, Biotechnology, Branches of biology, Neuroscience, Psychiatry, Psychiatric diagnosis, Learning disabilities, Childhood psychiatric disorders, Autism, Educational psychology, Attention deficit hyperactivity disorder, Neurocognition, Cognitive disorder, Autism spectrum

Regencell Bioscience Holdings Limited (NASDAQ:RGC) (“Regencell” or the “Company”), an early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine (“TCM”) for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder (“ADHD”) and Autism Spectrum Disorder (“ASD”), today announced the closing of its initial public offering (the “Offering”) of 2,300,000 ordinary shares at a public offering price of $9.50 per share.

Key Points: 
  • Regencell Bioscience Holdings Limited (NASDAQ:RGC) (Regencell or the Company), an early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD), today announced the closing of its initial public offering (the Offering) of 2,300,000 ordinary shares at a public offering price of $9.50 per share.
  • The Company received aggregate gross proceeds of $21.9 million from the Offering, before deducting underwriting discounts and other related expenses.
  • Regencell Bioscience Holdings Limited is an early-stage bioscience company that focuses on research, development and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, specifically ADHD and ASD.
  • All statements other than statements of historical fact in this announcement are forward-looking statements, including but not limited to, the Companys proposed Offering.

KeifeRx Receives FDA Acceptance of Investigational New Drug for Phase 3 Study of Nilotinib BE in Early Alzheimer's Disease

Retrieved on: 
Tuesday, July 20, 2021
Psychiatry, Cognitive disorders, Branches of biology, Learning disabilities, Psychiatric diagnosis, Neuroscience, Dementia, Orphan drugs, Nilotinib, Alzheimer's disease

The safety and efficacy of a Nilotinib BE will be investigated in individuals with dementia due to Alzheimer's disease with abnormal levels of brain amyloid and supporting clinical diagnosis of early Alzheimer's disease.

Key Points: 
  • The safety and efficacy of a Nilotinib BE will be investigated in individuals with dementia due to Alzheimer's disease with abnormal levels of brain amyloid and supporting clinical diagnosis of early Alzheimer's disease.
  • "Our Phase 3 study provides us the opportunity to gain valuable insights about the potential effectiveness of Nilotinib BE in treating early Alzheimer's.
  • KeifeRx will launch a national, multicenter, placebo-controlled, double-blind study of Nilotinib BE in early Alzheimer's disease.
  • The primary objectives of the study are to investigate the safety and efficacy of Nilotinib BE on the progression of dementia in early Alzheimer's disease.

Receptor Life Sciences Announces Initiation of IND-Opening Clinical PK Study of RLS102 for Irritability in Autism Spectrum Disorder

Retrieved on: 
Monday, July 19, 2021
Health, FDA, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Branches of biology, Psychiatric diagnosis, Psychiatry, Neuroscience, Autism, Developmental neuroscience, Developmental psychology, Learning disabilities, Autism spectrum, Irritability, Developmental disorder, Autism therapies

This first-in-class, pure synthetic CBD capsule is being investigated for the treatment of irritability in patients with autism spectrum disorder.

Key Points: 
  • This first-in-class, pure synthetic CBD capsule is being investigated for the treatment of irritability in patients with autism spectrum disorder.
  • Following the IND acceptance, RLS initiated a pharmacokinetic (PK), formulation selection study using RLS102 in healthy volunteers.
  • RLS102 has the potential to be a new treatment to reduce irritability in patients living with autism spectrum disorder, said Mark Theeuwes, President and CEO, Receptor Life Sciences.
  • A complex developmental disorder often associated with a high level of irritability, autism spectrum disorder (ASD) affects about 5 million adults in the United States ( https://www.cdc.gov/ncbddd/autism/features/adults-living-with-autism-spe... ).

Join the Race to End Alzheimer's by Featuring Your Loved One's Name On a Competitive Sports Car

Retrieved on: 
Saturday, July 17, 2021
Branches of biology, Cognitive disorders, Learning disabilities, Psychiatric diagnosis, Neuroscience, Psychiatry, Abnormal psychology, Alzheimer's disease, Dementia

The foundation has created a simple and meaningful process for people to support that "race" while also honoring their friends and family members.

Key Points: 
  • The foundation has created a simple and meaningful process for people to support that "race" while also honoring their friends and family members.
  • In 2017, Racing to End Alzheimer's began as a passion project for Frengs when his wife Mimi was diagnosed with early-onset Alzheimer's.
  • Frengs and the team behind Racing to End Alzheimer's have made the process of getting your loved one's name on a race car as easy as possible.
  • Learn more about Racing to End Alzheimer's or donate to remember your loved one on their website , r2endalz.org .

Caravel Autism Health Opens Third Autism Therapy Center for Families in the Treasure Valley

Retrieved on: 
Friday, July 16, 2021
Branches of biology, Psychiatric diagnosis, Psychiatry, Neuroscience, Autism, Pervasive developmental disorders, Learning disabilities

"ABA therapy is critically important for children who are on the autism spectrum," according to Anna McLane, MA, BCBA, clinical director for Caravel Autism Health in Meridian.

Key Points: 
  • "ABA therapy is critically important for children who are on the autism spectrum," according to Anna McLane, MA, BCBA, clinical director for Caravel Autism Health in Meridian.
  • By bringing three new autism therapy centers to the Treasure Valley, we have significantly expanded local availability and access to high-quality autism services.
  • Prior to opening the Meridian center, Caravel established autism therapy centers in Boise and Nampa earlier this year.
  • Since 2009, Caravel Autism Health has been devoted to helping families navigate the challenges of childhood autism.